Notice of Board Meeting

Next Day Disclosure Return

Completion of Placing of New Shares under General Mandate

Boan’s Dulaglutide Cleared by FDA for Clinical Trials

Boan Biotech today announced that it has received the U.S. FDA clearance for clinical trials of its dulaglutide injection (BA5101). BA5101 is a proposed biosimilar to Trulicity® intended for glycemic ...

Monthly Return of Equity Issuer on Movements in Securities for the month ended 31 July 2024

Approval Obtained for Initiating Clinical Trials for Dulaglutide Injection (BA5101) in the U.S.

Placing of New Shares under General Mandate

First in China: Boan Biotech’s Novel Investigational CD228-Directed ADC Approved for Clinical Trials

Yantai, July 25, 2024 – Boan Biotech today announced that its investigational drug candidate, a novel CD228-directed antibody drug conjugate (ADC) for injection codenamed BA1302, has been approv...

Approval Obtained for Initiating Clinical Trial for the Novel ADC Candidate BA1302 in China

Positive Profit Alert